BioNxt Solutions Net Cash Flow 2020-2025 | BNXTF

BioNxt Solutions net cash flow from 2020 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.

BioNxt Solutions Net Cash Flow 2020-2025 | BNXTF

BioNxt Solutions net cash flow from 2020 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$67.7B
Zoetis (ZTS)$65.3B
Daiichi Sankyo, - (DSNKY)$46.2B
Takeda Pharmaceutical (TAK)$45.9B
BeOne Medicines - (ONC)$31.6B
Sandoz Group AG (SDZNY)$25.8B
Summit Therapeutics (SMMT)$21.3B
Merck (MKKGY)$16.4B
Shionogi (SGIOY)$15.2B
United Therapeutics (UTHR)$13.6B
Neurocrine Biosciences (NBIX)$12.4B
Orion OYJ (ORINY)$10.8B
IPSEN (IPSEY)$10.4B
Madrigal Pharmaceuticals (MDGL)$7.7B
Corcept Therapeutics (CORT)$7.6B
Grifols, S.A (GRFS)$7.3B
Stevanato Group S.p.A (STVN)$7.2B
Ionis Pharmaceuticals (IONS)$6.6B
Hikma Pharmaceuticals Plc (HKMPF)$5.9B
Ono Pharmaceutical (OPHLF)$5.1B
Soleno Therapeutics (SLNO)$4.4B
Hypermarcas (HYPMY)$2.9B
NewAmsterdam Pharma (NAMS)$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
Crinetics Pharmaceuticals (CRNX)$2.5B
Catalyst Pharmaceuticals (CPRX)$2.4B
Centessa Pharmaceuticals (CNTA)$2.3B
Ocular Therapeutix (OCUL)$2.1B
Endo (NDOI)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.7B